RESUMEN
Reduced serum IgG and subclass levels have been demonstrated in children with chronic renal failure. To study possible causes of this reduction, we analysed B cell subset composition, T helper cell frequencies and immunoglobulin (Ig) production capacity in vitro in children with chronic renal failure, with or without dialysis treatment. B cell subsets were characterized by determining CD27, IgM, IgD and CD5 expression within the CD19(+) population. Intracellular expression of interferon (IFN)-gamma, interleukin (IL)-2 and IL-4 in PMA/ionomycin-stimulated peripheral blood mononuclear cells (PBMC) was used to evaluate T helper frequencies. The capacity of B cells to secrete Ig in vitro was determined by measuring IgG(1), IgG(2) and IgM in culture supernatants of anti-CD2/CD28 monoclonal antibody (MoAb)- or SAC/IL-2-stimulated PBMC. Memory B cell numbers (identified as percentage or absolute number of CD19(+) IgM-IgD- or CD19(+)CD27(+) lymphocytes) were lower in children treated with haemodialysis (HD), peritoneal dialysis (PD) and children with chronic renal failure before starting dialysis treatment (CRF) compared to healthy controls (HC) (P < 0.05). Compared with HC, CD5(+) (naive) B cells were reduced in HD-treated patients but not for PD or for children with chronic renal failure before starting dialysis treatment (CRF). No significant differences in CD4(+) T helper cell subsets were found between the groups. However, CRF children had a higher percentage of IFN-gamma producing CD8(+) T lymphocytes compared to HC (P = 0.02). Finally, IgG(1), IgG(2) and IgM production in vitro was similar in the four groups. In conclusion, significantly lower numbers of memory type B cells were found in children with chronic renal failure compared to healthy controls. This reduction may contribute to the low Ig levels found in these children.
Asunto(s)
Linfocitos B/inmunología , Memoria Inmunológica , Fallo Renal Crónico/inmunología , Adolescente , Biomarcadores/análisis , Antígenos CD5/análisis , Estudios de Casos y Controles , Niño , Preescolar , Humanos , Inmunoglobulina D/sangre , Inmunoglobulina M/sangre , Fallo Renal Crónico/terapia , Recuento de Linfocitos , Diálisis Peritoneal , Diálisis Renal , Miembro 7 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/análisisRESUMEN
AIM: The present studywas designed to retrospectively evaluate the use of renal biopsies prior to cyclophosphamide therapy. The aim of the study was to determine in how many cases histological outcome of the biopsies had subsequently changed the decision to treat or refrain from treatment. PATIENTS AND METHODS: Between January 1980 and September 2001, 85 children with steroid-sensitive nephrotic syndrome (SSNS) underwent a renal biopsy in the University Hospitals of Utrecht and Nijmegen before the start of an 8-week cyclophosphamide treatment. MCNS was suspected in all children because of the following criteria: edema, proteinuria, hypoalbuminemia, absence of macroscopic hematuria and in rare cases microscopic hematuria, no permanent hypertension, normal C3 serum level, a normal glomerular filtration rate as determined by creatinine clearance and age > 1 year. Cyclophosphamide therapy was indicated because of a frequently relapsing (FR) course of illness in 8 children, because of steroid dependence (SD) in 22 children and because of combined FR and SD in 55 children. Steroid-resistant children were excluded from this study. RESULTS: Histology confirmed the diagnosis MCNS in 84 out of 85 children. In addition to MCNS, IgA deposits were observed in renal specimens of 2 children. In 1 SD child, the initial diagnosis MCNS was changed 3 years later when a repeated biopsy showed progression into focal segmental glomerulosclerosis (FSGS). CONCLUSION: In summary, no renal biopsy is required prior to cytotoxic therapy in children with uncomplicated steroid-sensitive nephrotic syndrome.
Asunto(s)
Ciclofosfamida/uso terapéutico , Síndrome Nefrótico/tratamiento farmacológico , Síndrome Nefrótico/patología , Adolescente , Biopsia , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Síndrome Nefrótico/metabolismo , Estudios Retrospectivos , Esteroides/metabolismoAsunto(s)
Antibacterianos/uso terapéutico , Cefazolina/uso terapéutico , Ceftazidima/uso terapéutico , Cefalosporinas/uso terapéutico , Diálisis Peritoneal/efectos adversos , Peritonitis/tratamiento farmacológico , Vancomicina/uso terapéutico , Adulto , Niño , Quimioterapia Combinada , Humanos , Peritonitis/etiología , Guías de Práctica Clínica como AsuntoRESUMEN
Circulating nucleic acids in serum and plasma are common in a variety of disease conditions. Here, we focus (i) on our approach for the detection of various hepatitis B virus (HBV)-related nucleic acids in liver tissue and in serum, (ii) on the progression of the chronic HBV infection, (iii) on the relation of HBV-specific nucleic acids circulating in the blood of patients with hepatocellular carcinoma, and in general (iv) on the diagnostic potential of circulating HBV nucleic acids.
Asunto(s)
Carcinoma Hepatocelular/sangre , Portador Sano , Antígenos de Superficie de la Hepatitis B/genética , Virus de la Hepatitis B/genética , Neoplasias Hepáticas/sangre , Secuencia de Aminoácidos , Progresión de la Enfermedad , Humanos , Datos de Secuencia Molecular , Homología de Secuencia de Aminoácido , Transactivadores/química , Transactivadores/genética , Proteínas Reguladoras y Accesorias ViralesRESUMEN
OBJECTIVE: To evaluate the use of the combination of cefazolin and ceftazidime for initial treatment of peritoneal dialysis (PD)-related peritonitis in pediatric patients. DESIGN: Retrospective nonrandomized study. SETTING: Pediatric dialysis units of the University Medical Center of Utrecht and Nijmegen, The Netherlands. PATIENTS: 40 children (median age 5.4 years) who were treated with PD during the study period of 4.5 years. INTERVENTIONS: All 50 episodes of peritonitis that occurred during the study period were evaluated by review of medical records. Patients were given intraperitoneal ceftazidime 500 mg/L dialysis fluid, and cefazolin 500 mg/L as a loading dose, followed by a maintenance dose of ceftazidime 125 mg/L and cefazolin 100 mg/L, intraperitoneally, 4 times daily. Antibiotics were continued for 14 days. RESULTS: After identification of the causative microorganism, one of the antibiotics was discontinued in 34 cases, and the antibiotic schedule was adapted in 2 cases. All cases were initially cured within 3 days. In 5 cases (10%), there was a peritonitis with the same organism recurring within 2 weeks after completion of treatment. There were 4 cases of PD-related peritonitis caused by pseudomonas, all of which were cured. CONCLUSIONS: The antibiotic combination of cefazolin and ceftazidime is effective for the initial therapy of PD-related peritonitis in children. The toxic complications of aminoglycosides are avoided with this combination.
Asunto(s)
Cefazolina/administración & dosificación , Ceftazidima/administración & dosificación , Cefalosporinas/administración & dosificación , Quimioterapia Combinada/administración & dosificación , Peritonitis/tratamiento farmacológico , Adolescente , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Diálisis Peritoneal/efectos adversos , Diálisis Peritoneal Ambulatoria Continua/efectos adversos , Peritonitis/etiología , Peritonitis/microbiologíaRESUMEN
A substantial proportion of the worldwide liver cancer incidence is associated with chronic hepatitis B virus (HBV) infection. The therapeutic management of HBV infections is still problematic and novel antiviral strategies are urgently required. Using the peptide aptamer screening system, we aimed to isolate new molecules, which can block viral replication by interfering with capsid formation. Eight peptide aptamers were isolated from a randomized expression library, which specifically bound to the HBV core protein under intracellular conditions. One of them, named C1-1, efficiently inhibited viral capsid formation and, consequently, HBV replication and virion production. Hence, C1-1 is a novel model compound for inhibiting HBV replication by blocking capsid formation and provides a new basis for the development of therapeutic molecules with specific antiviral potential against HBV infections.
Asunto(s)
Antivirales/farmacología , Antígenos del Núcleo de la Hepatitis B/metabolismo , Hepatitis B/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Péptidos/farmacología , Secuencia de Aminoácidos , Antivirales/metabolismo , Aptámeros de Péptidos , Cápside/efectos de los fármacos , Virus de la Hepatitis B/efectos de los fármacos , Humanos , Neoplasias Hepáticas/virología , Datos de Secuencia Molecular , Biblioteca de Péptidos , Péptidos/química , Péptidos/metabolismo , Células Tumorales Cultivadas , Técnicas del Sistema de Dos Híbridos , Virión/efectos de los fármacos , Replicación Viral/efectos de los fármacosRESUMEN
PURPOSE: Beside the established maturation of hepatitis B virus (HBV) transcripts at a polyadenylation signal downstream of the HBV x protein open reading frame, maturation at an internal polyadenylation signal has been observed in the chronically infected liver. In the present study, it was the aim to identify the respective circulating full-length and truncated transcripts in plasma/serum of carriers. EXPERIMENTAL DESIGN: Nucleic acids extracted from sera were analyzed using established PCR and reverse transcription-PCR procedures targeted to HBV x protein gene regions. Amplification products were cloned and sequenced. RESULTS: Base substitution patterns were determined, which indicated infection stages advanced to different degrees regardless of the transcript type analyzed. HBV full-length RNA (fRNA) showed a high correlation with hepatitis B e antigen and viral DNA, indicative for a replicative infection. In contrast, truncated RNA (trRNA) appeared to be independent of hepatitis B e antigen and showed only a weak association with circulating viral DNA. No correlation was observed between the levels of trRNA and the apparent liver damage as reflected by alanine transaminase levels. An age-dependent representation of fRNA and trRNA was observed: fRNA decreased progressively to low levels, whereas trRNA remained at comparably high values. trRNA and RNA not polyadenylated at either of the two polyadenylation signals were detected even in the absence of any other conventional HBV seromarker, including viral DNA. This was shown for patients with cryptogenic cirrhosis and hepatitis C virus carriers. CONCLUSIONS: The identification of HBV RNA in human serum has a diagnostic potential for apparent and for inapparent infection stages.
Asunto(s)
Virus de la Hepatitis B/genética , Hepatitis B Crónica/virología , ARN Viral/sangre , Adolescente , Adulto , Factores de Edad , Alanina Transaminasa/sangre , Niño , Cartilla de ADN , ADN Complementario/química , ADN Complementario/genética , ADN Viral/sangre , ADN Viral/química , Variación Genética , Antígenos de Superficie de la Hepatitis B/sangre , Antígenos de Superficie de la Hepatitis B/genética , Antígenos e de la Hepatitis B/sangre , Antígenos e de la Hepatitis B/genética , Hepatitis B Crónica/sangre , Humanos , Persona de Mediana Edad , Oligodesoxirribonucleótidos/genética , Poli A/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Análisis de Secuencia de ADN , Transactivadores/sangre , Transactivadores/genética , Transcripción Genética , Proteínas Reguladoras y Accesorias Virales , Replicación Viral/genéticaAsunto(s)
Eritropoyetina/administración & dosificación , Diálisis Peritoneal , Adolescente , Anemia/sangre , Anemia/tratamiento farmacológico , Anemia/etiología , Niño , Preescolar , Soluciones para Diálisis , Femenino , Hemoglobinas/análisis , Humanos , Lactante , Fallo Renal Crónico/complicaciones , Masculino , Proteínas RecombinantesRESUMEN
OBJECTIVE: To study the adsorption of erythropoietin and growth hormone to dialysis bags and tubing. DESIGN: In vitro study in which radiolabeled erythropoietin and recombinant human growth hormone were added to small-volume (50- and 250-mL) dialysis bags. Recovery was measured after 15-minute dwells. Experiments were performed in triplicate. SETTING: University hospital. RESULTS: Adsorption of erythropoietin and growth hormone was less than 7%. CONCLUSION: Adsorption of erythropoietin and recombinant human growth hormone to dialysis bags and tubing is minimal. This finding provides another argument in favor of intraperitoneal therapy in pediatric peritoneal dialysis.
Asunto(s)
Eritropoyetina/farmacocinética , Hormona del Crecimiento/farmacocinética , Diálisis Peritoneal Ambulatoria Continua/instrumentación , Diálisis Peritoneal/instrumentación , Adsorción , Niño , Eritropoyetina/administración & dosificación , Hormona del Crecimiento/administración & dosificación , Humanos , Radioisótopos de YodoRESUMEN
OBJECTIVE: To provide guidelines on choosing dialysis solutions for children on chronic peritoneal dialysis (PD). SETTING: European Paediatric Peritoneal Dialysis Working Group. DATA SOURCE: Literature on the application of PD solutions in children (Evidence), and discussions within the group (Opinion). CONCLUSIONS: Glucose is the standard osmotic agent for PD in children (Evidence). The lowest glucose concentration needed should be used (Opinion). Low calcium solution (1.25 mmol/L) should be applied, wherever possible, with careful monitoring of parathyroid hormone levels (Opinion). The use of amino acid-containing dialysis fluids can be considered in malnourished children, although aggressive enteral nutrition is preferred (Opinion). There is insufficient evidence documenting the efficacy of intraperitoneally administered amino acids (Evidence). When ultrafiltration and/or solute removal are insufficient, polyglucose solutions are a welcome addition to the treatment of children on nocturnal intermittent PD (Evidence). However, in the absence of any reported long-term experience with children, their use must be closely monitored (Opinion). Bicarbonate would appear to be the preferred buffer for PD in children, but more in vivo studies are required before it replaces the present lactate-containing solutions (Evidence/Opinion).
Asunto(s)
Soluciones para Diálisis , Diálisis Peritoneal/normas , Acetatos , Aminoácidos , Bicarbonatos , Tampones (Química) , Niño , Soluciones para Diálisis/química , Soluciones para Diálisis/uso terapéutico , Glucanos , Glucosa , Humanos , Ácido Láctico , Ósmosis , Diálisis Peritoneal/métodos , Peritoneo/metabolismoRESUMEN
The use of recombinant human erythropoietin (rhEPO) has greatly facilitated the treatment of anemia in children with chronic renal failure, but is expensive. Several reports on adult patients have shown that supplementation with L-carnitine can decrease the requirement for rhEPO. The objective of this study was to investigate the effect of oral supplementation with L-carnitine on the rhEPO requirement in children on dialysis. We investigated 16 children on dialysis (11 hemodialysis, 5 peritoneal dialysis) with a median age of 10.2 years. All children were stable on rhEPO treatment at least 3 months before study entrance. After obtaining baseline data, all children were supplemented with L-carnitine 20 mg/kg/day. Data were collected for 26 weeks. Follow-up was completed for 12 patients (8 hemodialysis, 4 peritoneal dialysis). At baseline free carnitine (32+/-18 micromol/l) and total carnitine levels (54+/-37 micromol/l) were normal. At the end of the study free carnitine levels had increased to 97+/-56 micromol/l (P<0.05) and total carnitine levels to 163+/-90 micromol/l (P<0.05). There was no significant change in rhEPO requirement. Hemoglobin level or hematocrit did not change significantly during the study. In conclusion we could not demonstrate a beneficial effect of supplementation with L-carnitine on rhEPO requirement in children on dialysis.
Asunto(s)
Anemia/etiología , Carnitina/uso terapéutico , Eritropoyetina/uso terapéutico , Fallo Renal Crónico/terapia , Diálisis Peritoneal , Diálisis Renal , Administración Oral , Adolescente , Adulto , Carnitina/administración & dosificación , Carnitina/sangre , Niño , Preescolar , Relación Dosis-Respuesta a Droga , Femenino , Estudios de Seguimiento , Humanos , Lactante , Fallo Renal Crónico/complicaciones , Masculino , Proteínas Recombinantes , Factores de TiempoRESUMEN
Icodextrin use in adults provides sustained ultrafiltration (UF) in long-term dwells. No information is available on UF and metabolism in children. In 11 children, a volume of 1,049+/-138 ml/m2 of the study fluid (1.36% glucose, 7.5% icodextrin, 3.86% glucose) was administered for 12 h. Net UF with icodextrin (339+/-147 ml/1.73 m2) did not differ from UF with 3.86% glucose (450+/-306 ml/1.73 m2, P=0.53) and was higher than UF with 1.36% glucose (-87+/-239 ml/1.73 m2, P=0.003). Icodextrin added 0.52+/-0.07 to the weekly Kt/V. Over 6 weeks, icodextrin was used for 12-h daytime dwell. Total icodextrin reached a steady-state level of 2.91+/-1.22 g/l at 2 weeks. The main icodextrin metabolites were maltose, maltotriose, and maltotetraose. After 2 weeks, steady state levels were 2.02+/-0.66 mmol/l, 1.46+/-0.35 mmol/l, and 0.45+/-0.12 mmol/l. No icodextrin or metabolites were detectable 4 weeks after the study. We conclude that 7.5% icodextrin is capable of maintaining UF during 12-h dwell in children and is comparable to UF obtained with 3.86% glucose. Steady-state levels of icodextrin and metabolites were reached at 2 weeks and disappeared after the study.
Asunto(s)
Soluciones para Diálisis , Glucanos/uso terapéutico , Glucosa/uso terapéutico , Diálisis Peritoneal , Adolescente , Adulto , Glucemia/metabolismo , Niño , Preescolar , Femenino , Glucanos/farmacocinética , Glucosa/farmacocinética , Humanos , Icodextrina , Masculino , Maltosa/análogos & derivados , Maltosa/sangre , Oligosacáridos/sangre , UltrafiltraciónRESUMEN
BACKGROUND: Alport syndrome (AS) is a clinically and genetically heterogeneous renal disorder, predominantly affecting the type IV collagen alpha 3/alpha 4/alpha 5 network of the glomerular basement membrane (GBM). AS can be caused by mutations in any of the three genes encoding these type IV collagen chains. The majority of AS families (85%) are X-linked (XL-AS) involving mutations in the COL4A5 gene. Mutations in the COL4A3 and COL4A4 genes cause autosomal recessive AS (AR-AS), accounting for approximately 14% of the cases. Recently, autosomal dominant AS (AD-AS) was linked to the COL4A3/COL4A4 locus in a large family. METHODS: COL4A3 and COL4A4 cDNAs were generated by nested reverse transcription-polymerase chain reaction and were analyzed by DNA sequence analysis. Denaturating high-performance liquid chromatography (DHPLC) was used for mutation and segregation analysis at the genomic DNA level. RESULTS: In the AD-AS family, a splice site mutation resulting in skipping of exon 21 of the COL4A3 gene was detected. The mutation does not alter the reading frame and is predicted to result in a COL4A3 chain with an internal deletion. CONCLUSION: As the NC domain is intact, this chain may be incorporated and distort the collagen triple helix, thereby causing the dominant effect of the mutation. The finding of a specific COL4A3 mutation in AD-AS completes the spectrum of type IV collagen mutations in all genetic forms of AS.
Asunto(s)
Colágeno/genética , ADN Recombinante , Genes Dominantes , Mutación , Nefritis Hereditaria/genética , Adulto , Secuencia de Bases/genética , ADN Complementario/genética , Femenino , Humanos , Masculino , Ácidos Nucleicos Heterodúplex , LinajeRESUMEN
BACKGROUND: It is not clear whether low serum levels of IgG (subclasses), previously demonstrated in children on peritoneal dialysis (PD), are related to the PD procedure or to factors associated with chronic renal failure (CRF). The aim of our study was to analyze the effect of PD on serum and PD effluent (PDE) IgG and subclass levels in children with end-stage renal failure. METHODS: We measured albumin, IgG, IgA, IgM, and IgG subclasses in serum and PDE from children on PD (N = 40) and compared the serum values with those of children treated with hemodialysis (HD, N = 23) or presenting with CRF but not yet dialyzed (CRF; N = 63), and with a group of healthy controls (HCs; N = 67). Sixteen PD children could be followed sequentially from before starting PD and eight during a peritonitis episode. RESULTS: Forty percent of the PD children showed reduced serum IgG2 levels (P = 0.0003) compared with 35% in HD (P = 0.006), 33% in CRF (P = 0.001), and 9% in HC children. IgG1 deficiencies were observed in 25% of PD patients (P < 0.0001), 4% of HD (P = NS), 16% of CRF (P = 0.0005), and 0% of HC children. IgG3 and IgG4 deficiencies were observed less frequently. Peritoneal clearances were similar for total IgG, IgG1, IgG2, and IgG4, but were lower for IgG3 (P < 0.05). No relationships were found between clearances and age or duration of PD treatment. Total IgG (P = 0. 003) and IgG1 (P = 0.002) levels declined just after starting PD. Peritonitis was associated with temporarily increased peritoneal loss of Ig, while the serum concentrations were unaffected. No significant relationship was found between the peritonitis incidence and reduced IgG or subclasses. However, all children with two or more peritonitis episodes per year had a reduced Ig level. CONCLUSIONS: Although the mean serum concentrations of immunoglobulins were normal in all studied groups, a deficiency of one or more IgG subclasses was present in all groups with renal failure, suggesting inhibition of their synthesis by the uremic state. Ig deficiencies were more frequently found in PD, likely caused by protein loss in PDE. A high peritonitis incidence was associated with reduced serum Ig levels.
Asunto(s)
Inmunoglobulinas/análisis , Fallo Renal Crónico/inmunología , Fallo Renal Crónico/terapia , Diálisis Peritoneal , Enfermedad Aguda , Adolescente , Albúminas/metabolismo , Niño , Preescolar , Estudios Transversales , Soluciones para Diálisis/farmacocinética , Estudios de Seguimiento , Humanos , Inmunoglobulina A/análisis , Inmunoglobulina G/análisis , Inmunoglobulina M/análisis , Lactante , Estudios Longitudinales , Peritoneo/metabolismo , Peritonitis/inmunología , Peritonitis/terapiaRESUMEN
A 6-year-old boy developed macroscopic haematuria on the 4th day after appendectomy for acute appendicitis, at which the appendix was found to be perforated. During the next few days the urine secretion decreased and malaise, pain in the lower abdomen, nausea and vomiting occurred. On a management of ample fluid administration, the urine secretion recovered and the symptoms subsided in a few days. In the early postoperative stage after appendectomy in children the possibility should be kept in mind of the development of acute renal insufficiency due to bilateral ureteral obstruction as a result of oedema of the posterior bladder wall, even if by means of ultrasonography only mild to moderate abnormalities are noted. Awaiting decompression by means of the introduction of bilateral ureteric stents, in order to prevent irreversible renal damage, supportive therapy with fluid administration depending on the diuresis seems indicated.
Asunto(s)
Lesión Renal Aguda/etiología , Apendicectomía/efectos adversos , Edema/complicaciones , Obstrucción Ureteral/complicaciones , Enfermedades de la Vejiga Urinaria/complicaciones , Lesión Renal Aguda/terapia , Niño , Descompresión Quirúrgica/métodos , Edema/etiología , Fluidoterapia , Humanos , Masculino , Stents , Resultado del Tratamiento , Obstrucción Ureteral/etiología , Enfermedades de la Vejiga Urinaria/etiologíaRESUMEN
p53 mutations and binding of p53 to hepatitis B virus (HBV) x protein (HBx) have been suggested as alternative mechanisms of development of hepatocellular carcinomas (HCCs) in man, both processes resulting in intracellular accumulation of the protein which is detectable by immunohistochemical approaches. We have examined p53 expression in 149 explanted human livers, including 39 cases infected with HBV and 35 bearing HCC. p53 was demonstrated immunohistochemically in 51% of HCC samples (18/35), localized mainly in fast growing poorly differentiated areas. Accumulation of mutant p53 was verified by immunoprecipitation in most of the positive HCC samples (14/15), implying occurrence of p53 mutations. No cells positive for p53 were found in 354 preneoplastic hepatocellular lesions examined. This indicates that p53 mutation is associated with progression, rather than early development, of HCC in the low-aflatoxin B(1)-exposed region. The intracellular distribution patterns of p53 and HBx were different, with the former within nuclei and the latter confined to cytoplasmic compartment. HBx did not coimmunoprecipitate with p53. These data indicate that p53-HBx binding is infrequent, if it really occurs, in HBV-infected human liver, and that it cannot be a common mechanism of HBV-associated hepatocarcinogenesis. In addition, p53 accumulation was also observed in some parenchymal and ductular (oval) cells in cirrhotic livers and, more frequently, in fulminant hepatitis, being independent of HBx expression, and seemingly associated with the damage and/or regeneration of liver parenchyma, perhaps merely reflecting a cellular stress response.